- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05369884
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
10. maj 2022 opdateret af: Xiyuan Hospital of China Academy of Chinese Medical Sciences
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of WPQW Granule for Overlap of Non-Erosive Reflux Disease(NERD) and Diarrhea Predominant Diarrhea Irritable Bowel Syndrome(IBS-D)
Non-erosive reflux disease(NERD)and Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)are both the common refractory gastrointestinal diseases.
Patients, who suffered from overlapping symptoms of NERD and IBS-D, present more serious symptom manifestation, anxiety, and worse life quality than those with solely disease.
There is lack of effective treatment for overlapping gastrointestinal symptoms.
Traditional Chinese Medicine (TCM) syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence.
The purpose of this study is to evaluate the efficacy and safety of WPQW granule for the treatment of NERD overlapping IBS-D.
Studieoversigt
Status
Rekruttering
Intervention / Behandling
Detaljeret beskrivelse
Gastroesophageal reflux disease (GERD) is a chronic relapsing acid-peptic disorder that is caused by the reflux of gastric or duodenum content.
Non-erosive reflux disease(NERD), which account for 70%, is the most common type of GERD in the Asian population.
Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)is the mainly subtype of IBS, and the prevalence was found to be 46% in IBS.
Both diseases aforementioned are common and frequent chronic diseases in the world, and the pathogenesis of which has not been fully defined.
Current studies have shown that GERD can present in patients with IBS, vice versa.
Up to 79% of patients with IBS co-exist with GERD-like symptoms, and 71% of patients with GERD co-exist with IBS-like symptoms.
For those patients, they suffer from more serious symptom manifestation, anxiety, and worse life quality those with solely disease.
The diagnosis and treatment of Functional gastrointestinal disorders (FGIDs) mostly based on the idea of segmental diagnosis and single-target therapy in modern medicine, and there is lack of effective treatment for overlapping gastrointestinal symptoms.
The advantages of holistic diagnosis therapy and individualized treatment in Traditional Chinese Medicine(TCM)have attracted international attention, but there is still lack of high-level evidence-based medical evidence for the treatment of symptom overlap in FGIDs in TCM.
In this study, we propose to conduct a multicenter, randomized, double-blind, placebo-controlled clinical study of WPQW granule for the treatment of NERD overlapping IBS-D to evaluate the efficacy and safety of WPQW granule with the aim of obtaining high-level evidence-based medical evidence.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
216
Fase
- Tidlig fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Fengyun Wang, M.D
- Telefonnummer: +86(010)62835248
- E-mail: wfy811@163.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100091
- Rekruttering
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
-
Kontakt:
- Fengyun Wang, M.D
- Telefonnummer: +86(010)62835248
- E-mail: wfy811@163.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with NERD and IBS-D simultaneously
- Patients who present cardinal symptoms like reflux, heartburn, abdominal pain/bloating, diarrhea, etc
- Patients diagnosed with syndrome of intermingled cold and heat of traditional Chinese medicine
- Patients have informed consent and are willing to receive corresponding treatment
Exclusion Criteria:
- Patients with hiatal hernia
- Patients with upper gastrointestinal bleeding, peptic ulcer, gastrointestinal tumor, chronic atrophic gastritis with dysplasia
- Patients with other serious organic diseases, such as acute cardiovascular disease, acute and chronic pancreatitis, cirrhosis, abnormal liver function (transaminases more than 1.5 times of normal value), abnormal thyroid function, diabetes mellitus with a history of more than 10 years, chronic renal insufficiency, hematologic disorders, and hematologic disorders, etc
- Patients with neurological disease or psychiatric impairment like severe anxiety, depression requiring long-term drug treatment
- Patients who cannot stop taking acid suppressants for a long time
- Alcohol or drug dependency or abuse
- Pregnant or lactating women
- Patients who have a history of allergies to all the test drugs
- Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months
- Patients who, in the opinion of the investigator, are not suitable to participate in clinical trial
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental group
Oral administration of WPQW granule with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal.
The medication period was 4 weeks.
|
WPQW granule, 2 sachets / time, 3 times / day.
|
|
Placebo komparator: Control group
Oral administration of WPQW granule simulant,which containing 5% WPQW granule,with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal.
The medication period was 4 weeks.
|
WPQW granule simulant, 2 sachets / time, 3 times / day.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of visual analogue scale (VAS) score of symptoms of reflux and heartburn
Tidsramme: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
During the medication period, the patients recorded the reflux and heartburn episodes (frequency and duration) within 24 hours per day on the symptom diary card, and VAS scores for reflux and heartburn symptoms was calculated as the mean score of each symptom in the past week.
The episodes in the week before medication were used as the baseline, the mean score of any symptom decreased ≥50% from the baseline was recorded as response after weekly treatment, and the number of response weeks was considered effective if it was greater than 50% of the weeks of the whole treatment period.
|
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
|
Change of visual analogue scale (VAS) score of symptoms of abdominal pain and diarrhea
Tidsramme: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
During the medication period, the patients recorded the of abdominal pain (pain severity and frequency) and diarrhea (stool consistency and frequency based on Bristol stool form scale) within 24 hours per day on the symptom diary card.
VAS score was conducted for the most severe abdominal pain, and the mean score was calculated for each week, with the week of episodes prior to medication administration as the baseline.
It was considered effective when the weekly mean score decrease of at least 30% from baseline and the days of at least once type 6 or type 7 stool Bristol stool form every week decrease of at least 30% from baseline, referring to the efficacy evaluation of the technical guidelines for clinical studies of Chinese medicine for IBS published in 2017.
|
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of traditional Chinese Medicine syndrome score
Tidsramme: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
The symptoms related to syndrome of intermingled cold and heat were scored.
The cardinal symptom was scored 0, 2, 4, 6 and the secondary symptom scored 0, 1, 2, 3 respectively according to severity of each symptom.
Total symptom score represented the syndrome score.
Reduction in syndrome score represented Improvement.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of 36-item short-form (SF-36) score
Tidsramme: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Health status was evaluated by a 36-item short-form (SF-36) containing eight health concepts.
If the score descends, it indicates that the patient's condition has improved.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of FGI-checklist score
Tidsramme: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
A 20-item FGI-checklist was used to evaluate comprehensive symptom severity of Functional Gastrointestinal Disorder (FGID), which covering esophageal, dyspeptic and bowel symptoms.
If the score descends, it indicates that the patient's condition has improved.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of Hospital Anxiety and Depression Scale (HAD) score
Tidsramme: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Hospital Anxiety and Depression Scale (HAD) score was used to evaluate the efficacy of experimental drug.
Reduction in total score represented Improvement
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Xudong Tang, M.D, China Academy of Chinese Medical Sciences
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. december 2021
Primær færdiggørelse (Forventet)
1. maj 2023
Studieafslutning (Forventet)
1. maj 2023
Datoer for studieregistrering
Først indsendt
8. maj 2022
Først indsendt, der opfyldte QC-kriterier
10. maj 2022
Først opslået (Faktiske)
11. maj 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
11. maj 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. maj 2022
Sidst verificeret
1. december 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Patologiske processer
- Sygdom
- Tegn og symptomer, fordøjelsessystemet
- Gastrointestinale sygdomme
- Tyktarmssygdomme, funktionelle
- Tyktarmssygdomme
- Tarmsygdomme
- Esophageal Motilitetsforstyrrelser
- Deglutition lidelser
- Esophageale sygdomme
- Syndrom
- Irritabelt tarmsyndrom
- Diarré
- Gastroøsofageal refluks
Andre undersøgelses-id-numre
- ZYYCXTD-C-202010
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .